Cargando…

HCV incidence is associated with injecting partner age and HCV serostatus mixing in young adults who inject drugs in San Francisco

BACKGROUND: HCV incidence is increasing in the US, notably among younger people who inject drugs (PWID). In a cohort of young adult (age<30 years) PWID in San Francisco we examined whether ‘injecting partner mixing’ factors, i.e. age of partner and knowledge of their HCV serostatus, were associat...

Descripción completa

Detalles Bibliográficos
Autores principales: Page, Kimberly, Evans, Jennifer L., Hahn, Judith A., Vickerman, Peter, Shiboski, Stephen, Morris, Meghan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6903751/
https://www.ncbi.nlm.nih.gov/pubmed/31821365
http://dx.doi.org/10.1371/journal.pone.0226166
_version_ 1783477904449994752
author Page, Kimberly
Evans, Jennifer L.
Hahn, Judith A.
Vickerman, Peter
Shiboski, Stephen
Morris, Meghan D.
author_facet Page, Kimberly
Evans, Jennifer L.
Hahn, Judith A.
Vickerman, Peter
Shiboski, Stephen
Morris, Meghan D.
author_sort Page, Kimberly
collection PubMed
description BACKGROUND: HCV incidence is increasing in the US, notably among younger people who inject drugs (PWID). In a cohort of young adult (age<30 years) PWID in San Francisco we examined whether ‘injecting partner mixing’ factors, i.e. age of partner and knowledge of their HCV serostatus, were associated with HCV transmission. METHODS: In 448 susceptible PWID studied prospectively. All participants were asked to report characteristics and behaviors they engaged in with up to 3 injecting partners defined as “people whom you injected the most with” in the past month”. These partnerships did not specify that drugs or injecting equipment was shared. HCV incidence was estimated by age of up to 3 injecting partners, categorized as: (i) all <30; (ii) mixed-age (<&≥30); and (iii) all ≥30 years and perceived knowledge of the HCV status of participants’ injecting partners’ HCV status. Interaction was evaluated between partnership age categories and perceived HCV status of partners. RESULTS: Between 2006–2018, overall HCV incidence (/100 person years observation [pyo]) was 19.4 (95% CI: 16.4, 22.9). Incidence was highest in those with mixed-age partnerships: 28.5 (95% CI: 21.8, 37.1) and those whose partners were all <30 (23.9; 95% CI: 18.8, 30.4), and lowest if partners were ≥30 (7.5; 95% CI: 4.8, 11.8). In a multivariable analyses adjusting for age, sex (of index), injection frequency, and injection partnership ‘monogamy’, we found evidence for an interaction: the highest HCV incidence was seen in PWID whose partners were all <30 and who knew at least one of their partners was HCV-positive (58.9, 95% CI: 43.3, 80.0; p<0.01). CONCLUSIONS: Younger injectors are more likely to acquire HCV from their similarly-aged peers, than older injecting partners. Protective seroadaptive behavior may contribute to reduce incidence. These findings can inform new HCV prevention approaches for young PWID needed to curb the HCV epidemic.
format Online
Article
Text
id pubmed-6903751
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-69037512019-12-20 HCV incidence is associated with injecting partner age and HCV serostatus mixing in young adults who inject drugs in San Francisco Page, Kimberly Evans, Jennifer L. Hahn, Judith A. Vickerman, Peter Shiboski, Stephen Morris, Meghan D. PLoS One Research Article BACKGROUND: HCV incidence is increasing in the US, notably among younger people who inject drugs (PWID). In a cohort of young adult (age<30 years) PWID in San Francisco we examined whether ‘injecting partner mixing’ factors, i.e. age of partner and knowledge of their HCV serostatus, were associated with HCV transmission. METHODS: In 448 susceptible PWID studied prospectively. All participants were asked to report characteristics and behaviors they engaged in with up to 3 injecting partners defined as “people whom you injected the most with” in the past month”. These partnerships did not specify that drugs or injecting equipment was shared. HCV incidence was estimated by age of up to 3 injecting partners, categorized as: (i) all <30; (ii) mixed-age (<&≥30); and (iii) all ≥30 years and perceived knowledge of the HCV status of participants’ injecting partners’ HCV status. Interaction was evaluated between partnership age categories and perceived HCV status of partners. RESULTS: Between 2006–2018, overall HCV incidence (/100 person years observation [pyo]) was 19.4 (95% CI: 16.4, 22.9). Incidence was highest in those with mixed-age partnerships: 28.5 (95% CI: 21.8, 37.1) and those whose partners were all <30 (23.9; 95% CI: 18.8, 30.4), and lowest if partners were ≥30 (7.5; 95% CI: 4.8, 11.8). In a multivariable analyses adjusting for age, sex (of index), injection frequency, and injection partnership ‘monogamy’, we found evidence for an interaction: the highest HCV incidence was seen in PWID whose partners were all <30 and who knew at least one of their partners was HCV-positive (58.9, 95% CI: 43.3, 80.0; p<0.01). CONCLUSIONS: Younger injectors are more likely to acquire HCV from their similarly-aged peers, than older injecting partners. Protective seroadaptive behavior may contribute to reduce incidence. These findings can inform new HCV prevention approaches for young PWID needed to curb the HCV epidemic. Public Library of Science 2019-12-10 /pmc/articles/PMC6903751/ /pubmed/31821365 http://dx.doi.org/10.1371/journal.pone.0226166 Text en © 2019 Page et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Page, Kimberly
Evans, Jennifer L.
Hahn, Judith A.
Vickerman, Peter
Shiboski, Stephen
Morris, Meghan D.
HCV incidence is associated with injecting partner age and HCV serostatus mixing in young adults who inject drugs in San Francisco
title HCV incidence is associated with injecting partner age and HCV serostatus mixing in young adults who inject drugs in San Francisco
title_full HCV incidence is associated with injecting partner age and HCV serostatus mixing in young adults who inject drugs in San Francisco
title_fullStr HCV incidence is associated with injecting partner age and HCV serostatus mixing in young adults who inject drugs in San Francisco
title_full_unstemmed HCV incidence is associated with injecting partner age and HCV serostatus mixing in young adults who inject drugs in San Francisco
title_short HCV incidence is associated with injecting partner age and HCV serostatus mixing in young adults who inject drugs in San Francisco
title_sort hcv incidence is associated with injecting partner age and hcv serostatus mixing in young adults who inject drugs in san francisco
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6903751/
https://www.ncbi.nlm.nih.gov/pubmed/31821365
http://dx.doi.org/10.1371/journal.pone.0226166
work_keys_str_mv AT pagekimberly hcvincidenceisassociatedwithinjectingpartnerageandhcvserostatusmixinginyoungadultswhoinjectdrugsinsanfrancisco
AT evansjenniferl hcvincidenceisassociatedwithinjectingpartnerageandhcvserostatusmixinginyoungadultswhoinjectdrugsinsanfrancisco
AT hahnjuditha hcvincidenceisassociatedwithinjectingpartnerageandhcvserostatusmixinginyoungadultswhoinjectdrugsinsanfrancisco
AT vickermanpeter hcvincidenceisassociatedwithinjectingpartnerageandhcvserostatusmixinginyoungadultswhoinjectdrugsinsanfrancisco
AT shiboskistephen hcvincidenceisassociatedwithinjectingpartnerageandhcvserostatusmixinginyoungadultswhoinjectdrugsinsanfrancisco
AT morrismeghand hcvincidenceisassociatedwithinjectingpartnerageandhcvserostatusmixinginyoungadultswhoinjectdrugsinsanfrancisco